DoW Rare Cancers Idea Development Award

The Rare Cancers Research Program Idea Development Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs. This initiative was established to advance research focused on rare cancers, defined as cancers affecting six or fewer individuals per 100,000 annually in the United States. Since its inception in 2020, the program has received significant congressional appropriations to support high-impact scientific investigations. The overarching goal is to improve outcomes for patients with rare cancers, including service members, veterans, their families, and the broader public, by accelerating discovery and expanding the scientific understanding of these diseases. This funding opportunity is designed to support innovative research ideas that are ready for further development and have the potential to produce meaningful scientific breakthroughs. Applicants are required to present well-supported hypotheses backed by preliminary data, although such data do not necessarily need to originate from the specific rare cancer under study. The program emphasizes high-impact research that can lead to major advancements, particularly in areas such as disease biology, preclinical model development, therapeutic strategies, and the application of artificial intelligence and machine learning in cancer research. The award provides funding through a grant mechanism with a maximum total cost of 490000 dollars per project over a period of up to three years. The program anticipates allocating approximately 7350000 dollars in total funding to support around 15 awards. Allowable costs include travel for collaboration and dissemination of results, while restrictions prohibit funding for clinical trials, tuition, and excessive travel expenses. There is no cost-sharing requirement, making the program accessible to a wide range of applicants. Eligibility for this opportunity is broad and inclusive, encompassing both domestic and international organizations, including for-profit and nonprofit entities, academic institutions, and government organizations. Independent investigators at all career stages may apply as principal investigators, provided they are affiliated with an eligible organization. However, each investigator may only serve as a principal investigator on one application for this funding cycle. Awards are granted to organizations rather than individuals. The application process is conducted in two stages. Applicants must first submit a pre-application through the Electronic Biomedical Research Application Portal, which includes a concise narrative outlining the research hypothesis, objectives, and potential impact. Following review, selected applicants are invited to submit a full application through either eBRAP or Grants.gov, depending on their organizational status. The full application requires detailed documentation, including a project narrative, technical and lay abstracts, supporting documentation, and various compliance and planning documents. Applications are evaluated through a rigorous two-tier review process. The first stage is a peer review assessing scientific merit, feasibility, and impact, while the second stage is a programmatic review that considers alignment with program priorities and overall portfolio balance. Key evaluation criteria include the strength of the research strategy, the potential impact on rare cancer outcomes, and the qualifications of the research team. Budget appropriateness and institutional support are also considered as part of the overall evaluation. The timeline for this opportunity includes a pre-application deadline in August 2026, followed by invitations for full applications in September 2026. Full applications are due in November 2026, with peer review scheduled for early 2027 and programmatic review shortly thereafter. Awards are expected to be finalized by September 2027. Applicants are encouraged to ensure all required registrations are completed in advance and to adhere strictly to submission requirements to avoid administrative rejection.

Ensure strong preliminary data and clear high-impact hypothesis aligned with focus areas; emphasize relevance to rare cancers and patient outcomes